跳到正文
原文
Pfizer Inc.· @pfizer · X·· 13 天前AI 评分12
AI 导读

治疗耐药是晚期前列腺癌面临的最大挑战之一,使疾病更难治疗,也凸显了对新方法的需求。 在辉瑞,我们的研究人员正在研究EZH2,以及靶向它是否有助于恢复对激素治疗的敏感性。 了解更多:https://bit.ly/3UwUcDl

正文

Treatment resistance is one of the biggest challenges in advanced prostate cancer, making the disease more difficult to treat and highlighting the need for new approaches.

At Pfizer, our researchers are studying EZH2 and whether targeting it could help restore sensitivity to hormone therapy.

Learn more: https://bit.ly/3UwUcDl

来源:Pfizer Inc. · x.com